View Post

Physicians Discuss Role of Elacestrant in ER+ Metastatic Breast Cancer

In In The News by Barbara Jacoby

From: targetedonc.com During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants their reactions to the data from the phase 3 EMERALD study of elacestrant for patients with metastatic ER+ breast cancer. DISCUSSION QUESTIONS What are your reactions to the efficacy data from the phase 3 EMERALD study (NCT03778931) of elacestrant (Orserdu)?​ What are your reactions to …

View Post

Which First-Line Breast Cancer Therapy Is Right for Me?

In In The News by Barbara Jacoby

From: healthline.com Knowing where to turn next with your breast cancer treatment can be a tough decision. But understanding the different types of therapies available for metastatic breast cancer can help ensure you know what’s best for you. Hormone and targeted therapies Hormonal therapies The first-line treatment for advanced hormone receptor-positive (estrogen receptor-positive or progesterone receptor-positive) breast cancer is usually …

View Post

Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer

In In The News by Barbara Jacoby

B:y American Society of Clinical Oncology From: ascopubs.org PURPOSE Given the heterogeneity and improvement in outcomes for metastatic breast cancer (MBC), we developed a staging system that refines prognostic estimates for patients with metastatic cancer at the time of initial diagnosis, de novo MBC (dnMBC), on the basis of survival outcomes and disease-related variables. METHODS Patients with dnMBC (2010-2016) were …

View Post

Updates on SERD Trials for Metastatic Breast Cancer

In In The News by Barbara Jacoby

From: targetedonc.com Targeted OncologyTM: What makes ESR1 mutations significant to patients with metastatic breast cancer treatment? HURVITZ: The common or defined ESR1 mutations [are in] different regions and the hotspot, the area with the largest number of mutations, activating mutations in ESR1 are found in the ligand binding domain and AFT2.1 The most common are [E380Q, Y538 C/D/H/N/S, and D538G/N], …

View Post

Dr. Kaklamani on CDK4/6 Inhibition Prior to Elacestrant in ER+/HER2– Breast Cancer

In In The News by Barbara Jacoby

By: Virginia Kaklamani, MD, DSc From: onclive.com Virginia Kaklamani, MD, professor of medicine, Division of Hematology/Oncology, leader, Breast Cancer Program, UT Health San Antonio MD Anderson Cancer Center, discusses the utilization of elacestrant (Orserdu) following treatment with CDK4/6 inhibitors in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer. At the 2022 San Antonio Breast Cancer Symposium (SABCS), investigators presented …

View Post

FDA OKs Elacestrant for ESR1 + Advanced, Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: M. Alexander Otto, PA, MMS From: medscape.com The US Food and Drug Administration approved elacestrant (Orserdu, Stemline Therapeutics, Inc) for postmenopausal women or men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that progressed on at least one line of endocrine therapy. The agency also approved the Guardant360 CDx assay as a companion diagnostic to identify breast cancer …

View Post

Anti-CDK4/6 in Metastatic Breast Cancer Showed Further Benefits at SABCS

In In The News by Barbara Jacoby

By: Greg Laub From: medpagetoday.com At the San Antonio Breast Cancer Symposium (SABCS)opens in a new tab or window, an update of the phase III monarchE trial showed an increasing benefit from the addition of abemaciclib (Verzenio) to adjuvant endocrine therapy for hormone receptor (HR)-positive/HER2-negative breast cancer, regardless of Ki-67 status. Meanwhile, the phase II RIGHT Choiceopens in a new …

View Post

Justin Trogdon, PhD, on Sequencing Single-Agent Chemo in Metastatic Cancer

In In The News by Barbara Jacoby

By: Jeff Minerd From: medpagetoday.com A cost-effectiveness study provided guidance on optimal treatment sequencing of single-agent chemotherapy options for women with metastatic breast cancer. “In this setting where multiple single-agent chemotherapy options are recommended by clinical guidelines and share similar survival and adverse event trajectories, treatment sequencing approaches that minimize costs early may improve the value of care,” said Stephanie …

View Post

Which Studies Will be Practice Changing in Metastatic Breast Cancer?

In In The News by Barbara Jacoby

By: Greg Lau From: medpagetoday.com Promising findings from various clinical trials at the San Antonio Breast Cancer Symposiumopens in a new tab or window (SABCS) have the metastatic breast cancer research community excited about the future of treatment. In this exclusive MedPage Today video, Jason Aboudi Mouabbi, MD, assistant professor in the Department of Breast Medical Oncology at the University …

View Post

SABCS Trials Show Improved Outcomes in Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Greg Laub From: medpagetoday.com Oral selective estrogen receptor downregulators, or SERDs as they’re known, have now come into the market and are coming out of trials, I should say, and are being tested in phase II and now in phase III trials. The first one to report mature data from the phase III trial was elacestrant [Orserdu], which was …